We use cookies to improve your experience and for marketing. Read our cookie policy or manage cookies.

Accept essential cookies
Accept all cookies
U.S. Pharmaceutical Preparation Market. Analysis And Forecast to 2030
Report Update: Feb 1, 2025

U.S. Pharmaceutical Preparation Market. Analysis And Forecast to 2030

Single report
Sent by email within 24h (Mon-Fri)
What's the difference?
Subscription
Online access and download
from $350/month

Get instant access to more than 2 million reports, dashboards, and datasets on the IndexBox Platform.

View Pricing
Dec 20, 2024

Novo Nordisk Shares Plummet as Weight-Loss Drug Trials Disappoint

Novo Nordisk A/S faced a significant setback as its shares experienced the largest drop on record following the underwhelming results of its experimental obesity treatment, CagriSema. The results, which can be read in detail here, show that patients lost an average of 20.4% of their body weight over 68 weeks, falling short of the company's projection of a 25% reduction. The Danish pharmaceutical giant had high hopes for CagriSema to further cement its dominant position in the rapidly expanding $130 billion weight-loss market projected by 2030, according to data from IndexBox.

The trial's outcome puts CagriSema on par with Eli Lilly & Co.'s Zepbound, which has been available in the market, while CagriSema was expected to outperform. The competition intensifies as Eli Lilly's next-generation product, retatrutide, continues to show promising results with a 24% weight reduction in prior studies. Novo Nordisk's failure to meet expectations led to a 27% plunge in its share value on the Copenhagen market, equating to a loss exceeding $120 billion from the company's market valuation. Concurrently, Eli Lilly's shares saw a 10% increase in premarket US trading.

Analysts suggest the side effects of CagriSema may have prevented patients from maintaining the treatment regimen, leading to this less-than-anticipated outcome. Jefferies analyst Peter Welford expressed that investors had anticipated the weight loss to range between 25% to 27%. The results add pressure on Novo Nordisk's pipeline, with significant expectations now placed on amycretin, which is still in the early stages of clinical testing.

Despite the setback, Novo Nordisk plans to present the trial results for regulatory review by next year, maintaining optimism about CagriSema's potential impact on their portfolio, which heavily relies on new products following Wegovy's looming patent expiration in the early 2030s.

Source: IndexBox Market Intelligence Platform

This report provides an in-depth analysis of the pharmaceutical preparation market in the U.S.. Within it, you will discover the latest data on market trends and opportunities by country, consumption, production and price developments, as well as the global trade (imports and exports). The forecast exhibits the market prospects through 2030.

Product coverage:

  • NAICS 325412 - Pharmaceutical preparation manufacturing

Companies mentioned:

  • Pfizer Inc.
  • Merck & Co.
  • Abbott Laboratories
  • Abbvie Inc.
  • Eli Lilly and Company
  • Bristol-Myers Squibb Company
  • Genentech
  • Baxter International
  • Allergan
  • Biogen, Glaxosmithkline
  • Celgene Corporation
  • Hospira
  • Alere
  • Perrigo Company
  • Mylan Inc.
  • Regeneron Pharmaceuticals
  • Novartis Corporation
  • Alexion Pharmaceuticals
  • Genzyme Corporation
  • Zoetis
  • Sanofi US Services
  • Olympus Partners
  • Valeant Pharmaceuticals International
  • Merck Sharp & Dohme Corp.
  • Glaxosmithkline Holdings (Americas)
  • Wyeth
  • Astrazeneca Pharmaceuticals
  • Actavis Inc.
  • Alcon Laboratories Holding Corporation
  • Roche Holdings

Country coverage:

  • United States

Data coverage:

  • Market volume and value
  • Per Capita consumption
  • Forecast of the market dynamics in the medium term
  • Trade (exports and imports) in the U.S.
  • Export and import prices
  • Market trends, drivers and restraints
  • Key market players and their profiles

Reasons to buy this report:

  • Take advantage of the latest data
  • Find deeper insights into current market developments
  • Discover vital success factors affecting the market

This report is designed for manufacturers, distributors, importers, and wholesalers, as well as for investors, consultants and advisors.

In this report, you can find information that helps you to make informed decisions on the following issues:

  1. How to diversify your business and benefit from new market opportunities
  2. How to load your idle production capacity
  3. How to boost your sales on overseas markets
  4. How to increase your profit margins
  5. How to make your supply chain more sustainable
  6. How to reduce your production and supply chain costs
  7. How to outsource production to other countries
  8. How to prepare your business for global expansion

While doing this research, we combine the accumulated expertise of our analysts and the capabilities of artificial intelligence. The AI-based platform, developed by our data scientists, constitutes the key working tool for business analysts, empowering them to discover deep insights and ideas from the marketing data.

  1. 1. INTRODUCTION

    Making Data-Driven Decisions to Grow Your Business

    1. REPORT DESCRIPTION
    2. RESEARCH METHODOLOGY AND AI PLATFORM
    3. DATA-DRIVEN DECISIONS FOR YOUR BUSINESS
    4. GLOSSARY AND SPECIFIC TERMS

  2. 2. EXECUTIVE SUMMARY

    A Quick Overview of Market Performance

    1. KEY FINDINGS
    2. MARKET TRENDS This Chapter is Available Only for the Professional Edition PRO

  3. 3. MARKET OVERVIEW

    Understanding the Current State of The Market and Its Prospects

    1. MARKET SIZE
    2. MARKET STRUCTURE
    3. TRADE BALANCE
    4. PER CAPITA CONSUMPTION
    5. MARKET FORECAST TO 2030

  4. 4. MOST PROMISING PRODUCT

    Finding New Products to Diversify Your Business

    This Chapter is Available Only for the Professional Edition PRO
    1. TOP PRODUCTS TO DIVERSIFY YOUR BUSINESS
    2. BEST-SELLING PRODUCTS
    3. MOST CONSUMED PRODUCT
    4. MOST TRADED PRODUCT
    5. MOST PROFITABLE PRODUCT FOR EXPORT

  5. 5. MOST PROMISING SUPPLYING COUNTRIES

    Choosing the Best Countries to Establish Your Sustainable Supply Chain

    This Chapter is Available Only for the Professional Edition PRO
    1. TOP COUNTRIES TO SOURCE YOUR PRODUCT
    2. TOP PRODUCING COUNTRIES
    3. TOP EXPORTING COUNTRIES
    4. LOW-COST EXPORTING COUNTRIES

  6. 6. MOST PROMISING OVERSEAS MARKETS

    Choosing the Best Countries to Boost Your Exports

    This Chapter is Available Only for the Professional Edition PRO
    1. TOP OVERSEAS MARKETS FOR EXPORTING YOUR PRODUCT
    2. TOP CONSUMING MARKETS
    3. UNSATURATED MARKETS
    4. TOP IMPORTING MARKETS
    5. MOST PROFITABLE MARKETS

  7. 7. PRODUCTION

    The Latest Trends and Insights into The Industry

    1. PRODUCTION VOLUME AND VALUE

  8. 8. IMPORTS

    The Largest Import Supplying Countries

    1. IMPORTS FROM 2012–2024
    2. IMPORTS BY COUNTRY
    3. IMPORT PRICES BY COUNTRY

  9. 9. EXPORTS

    The Largest Destinations for Exports

    1. EXPORTS FROM 2012–2024
    2. EXPORTS BY COUNTRY
    3. EXPORT PRICES BY COUNTRY

  10. 10. PROFILES OF MAJOR PRODUCERS

    The Largest Producers on The Market and Their Profiles

    This Chapter is Available Only for the Professional Edition PRO

  11. LIST OF TABLES

    1. Key Findings In 2024
    2. Market Volume, In Physical Terms, 2012–2024
    3. Market Value, 2012–2024
    4. Per Capita Consumption In 2012-2024
    5. Imports, In Physical Terms, By Country, 2012–2024
    6. Imports, In Value Terms, By Country, 2012–2024
    7. Import Prices, By Country Of Origin, 2012–2024
    8. Exports, In Physical Terms, By Country, 2012–2024
    9. Exports, In Value Terms, By Country, 2012–2024
    10. Export Prices, By Country Of Destination, 2012–2024

  12. LIST OF FIGURES

    1. Market Volume, In Physical Terms, 2012–2024
    2. Market Value, 2012–2024
    3. Market Structure – Domestic Supply vs. Imports, In Physical Terms, 2012-2024
    4. Market Structure – Domestic Supply vs. Imports, In Value Terms, 2012-2024
    5. Trade Balance, In Physical Terms, 2012-2024
    6. Trade Balance, In Value Terms, 2012-2024
    7. Per Capita Consumption, 2012-2024
    8. Market Volume Forecast to 2030
    9. Market Value Forecast to 2030
    10. Products: Market Size And Growth, By Type
    11. Products: Average Per Capita Consumption, By Type
    12. Products: Exports And Growth, By Type
    13. Products: Export Prices And Growth, By Type
    14. Production Volume And Growth
    15. Exports And Growth
    16. Export Prices And Growth
    17. Market Size And Growth
    18. Per Capita Consumption
    19. Imports And Growth
    20. Import Prices
    21. Production, In Physical Terms, 2012–2024
    22. Production, In Value Terms, 2012–2024
    23. Imports, In Physical Terms, 2012–2024
    24. Imports, In Value Terms, 2012–2024
    25. Imports, In Physical Terms, By Country, 2024
    26. Imports, In Physical Terms, By Country, 2012–2024
    27. Imports, In Value Terms, By Country, 2012–2024
    28. Import Prices, By Country Of Origin, 2012–2024
    29. Exports, In Physical Terms, 2012–2024
    30. Exports, In Value Terms, 2012–2024
    31. Exports, In Physical Terms, By Country, 2024
    32. Exports, In Physical Terms, By Country, 2012–2024
    33. Exports, In Value Terms, By Country, 2012–2024
    34. Export Prices, By Country Of Destination, 2012–2024

Recommended posts

Free Data: Pharmaceutical Preparation - United States
Table
Pharmaceutical Preparation - United States - Table
Dashboard
Pharmaceutical Preparation - United States - Dashboard
Report
Pharmaceutical Preparation - United States - Report